Key takeaways
- GLOW is a seller name for one vial mixing GHK-Cu, BPC-157 and TB-500; KLOW is the same mix with a fourth peptide, KPV.
- We found no published study or registered trial of either mix, and no study comparing the two (PubMed and ClinicalTrials.gov, 21 Nov 2026).
- What the fourth component adds is KPV’s own record: a 2008 mouse and cell study, with no clinical studies or human exposure data found by FDA staff.
- HHS’s draft compounding policy of October 2026, which is not an approval, lists BPC-157, TB-500 and KPV but not GHK-Cu, and covers single-ingredient products only.
- WADA names BPC-157 and TB-500 as prohibited at all times; it does not name GHK-Cu or KPV, and says a peptide not specifically named “may still be prohibited”.
01GLOW and KLOW side by side
The same questions, asked of both names. Dated 21 November 2026.
| Question | GLOW | KLOW |
|---|---|---|
| What the name refers to | A seller name for one vial that mixes three peptides | A seller name for one vial that mixes four peptides |
| Listed components | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| Studied as a mix | No study found, in any species | No study found, in any species |
| Compared with the other | No study found | No study found |
| Evidence tier of the studies cited here, component by component | GHK-Cu: small skin studies in people (T2), plus animal and cell studies. BPC-157: small human studies (T2) and animal studies (T3). TB-500: animal and cell studies (T3, T4) | The same three, plus KPV: a mouse and cell study (T3, T4) |
| Human data for the component that differs | No fourth component | FDA staff found no clinical studies or human exposure data for KPV |
| United States | FDA’s drug database lists no medicine containing GHK-Cu, BPC-157 or TB-500. HHS’s draft compounding policy of October 2026, which is not an approval, lists BPC-157 and TB-500, not GHK-Cu, and covers single-ingredient products only | The same, and KPV is on the HHS list too. FDA staff say KPV is not a component of an FDA-approved drug |
| Australia | BPC-157 and TB-500 are listed in Schedule 4, prescription-only medicines, and Appendix D of the Poisons Standard October 2026. The TGA says many peptide products promoted online “are unapproved therapeutic goods and may be unlawful to import, supply or advertise”. We searched the Standard for GHK-Cu’s names and found no entry by name; it has group entries for copper compounds. We draw no scheduling conclusion of our own | The same. The TGA says many peptide products promoted online “are unapproved therapeutic goods and may be unlawful to import, supply or advertise”. We searched the Standard for KPV as well and found no entry by name. We draw no scheduling conclusion of our own |
| Sport (WADA 2026 and 2027 Lists) | BPC-157 (class S0) and TB-500 (class S2.3) are named as prohibited at all times. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited” | The same. KPV is not named either, and WADA says a peptide not specifically named “may still be prohibited” |
| Identities a lab report has to confirm | Three | Four |
Each name has its own page: what is the “GLOW peptide”? and what is the “KLOW peptide”?
02What does the fourth component, KPV, add in published research?
One more compound, with its own, thinner record. Nothing about the mix.
A fourth molecule
KPV is a three-amino-acid peptide, lysine–proline–valine. FDA’s 2026 briefing describes it as a fragment of the hormone α-MSH.
A mouse and cell record
A 2008 study used two chemically induced forms of colitis in mice and three human cell lines, and measured inflammatory signalling. FDA staff found no clinical studies or human exposure data.
A fourth identity to confirm
A lab report for the four-peptide mix has one more compound to identify and measure. FDA staff assessed two forms of KPV, the free base and the acetate salt, and judged neither well characterised.
What KPV does not add is any study of KPV together with one of the other three. The two papers we found that name it beside GHK-Cu, BPC-157 or TB-500 are reviews (PubMed, 21 November 2026). FDA staff also write that its molecular targets “remain unknown” and that they identified no pharmacokinetic study. The full profile: KPV.
03Has any study compared GLOW and KLOW?
Not that we found. We found no study of either mix on its own, so there is nothing to compare.
On 21 November 2026 we searched PubMed with the component names quoted and unquoted. No paper names all four. Seven papers name GHK-Cu and BPC-157 together with TB-500 or thymosin β4, and each is a review, commentary or letter; none gave the three to cells, animals or people. ClinicalTrials.gov lists no trial that gives two or more of the components together.
That is why this page gives no verdict on which is “better”. There is no measurement to base one on. Evidence attaches to what was studied: peptide blends: one vial, no shared evidence.
04How do regulators and WADA treat each component?
Component by component. None of the status documents we read names either mix.
- Sep 2023FDA Category 2
BPC-157 and TB-500, listed for both mixes, and KPV, listed for KLOW only, enter FDA’s list of compounding substances that raise significant safety risks.
- 22 Apr 2026Out of Category 2
HHS records that neither the placement nor the removal changed the status of the three under section 503A.
- 14 May 2026GHK-Cu back under evaluation
FDA’s updated list returns GHK-Cu, listed for both mixes, to Category 1, “except for injectable routes of administration”.
- 23–24 Jul 2026Advisory committee meets
FDA staff propose not adding BPC-157, TB-500 or KPV to the 503A bulks list. HHS records that the committee voted in favour of each.
- 1 Oct 2026Poisons Standard October 2026 in force
Australia’s current standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D.
- 30 Oct 2026HHS draft policy published
It names six peptides, including BPC-157, TB-500 and KPV, and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice calls it a draft that “is not binding”.
- 1 Jan 2027WADA 2027 List takes effect
Its S0 class adds “peptides” to its examples. BPC-157 and TB-500 remain named.
In the UK, the emc database of licensed-medicine information returned no results for any of the four names on 21 November 2026; it is not the full UK register. Country by country, for each component: the KLOW page and the dated tracker, regulatory status. Sport: peptides and anti-doping.
05What we don’t know, and what would have to be studied
There is no evidence to rank one mix above the other. These are the studies that would be needed.
Whether the peptides stay intact together in one vial, and for how long. We found no published data for three peptides or for four.
The same model and the same measures, with a group for each peptide alone and a group for the mix. A 2026 rat study had a combination group for two of the peptides, BPC-157 and TB-500; we found none for three or four.
A direct comparison in which KPV is the only difference. We found none, published or registered.
Controlled studies, starting with how the body absorbs and clears each component. FDA staff identified no pharmacokinetic study of KPV.
How to check what a mixed vial holds: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.